Johnson & Johnson stock holds firm on earnings and dividend strength

Johnson & Johnson (US4781601046) is supported by a 2025 sales base of $88.8 billion, a 16.2% adjusted operating margin, and 2026 guidance for about $91.0 billion in sales at the midpoint. The company also lifted its quarterly dividend to $1.30 per share for 2026 and reported full-year 2025 adjusted earnings of $10.57 per share.

2025 sales reached $88.8 billion

Johnson & Johnson reported 2025 worldwide sales of $88.8 billion, up 5.2% from $84.8 billion in 2024, according to its annual report. That growth came alongside a 16.2% adjusted operating margin, which helps explain why the company continues to trade as a defensive large-cap health care name.

The margin profile matters because the company is balancing scale with litigation and restructuring costs while still expanding its earnings base. Adjusted earnings per share came to $10.57 in 2025, up from $9.97 in 2024, a gain of 6.0% year on year.

2026 guidance centers on $91.0 billion

For 2026, Johnson & Johnson guided to sales of $89.2 billion to $90.0 billion, with a midpoint of about $89.6 billion to $91.0 billion depending on the reporting basis used in company materials. The guidance range gives investors a concrete reference point after a year in which the company converted mid-single-digit revenue growth into higher earnings.

Full-year 2025 operating cash flow remained a key support factor at $23.8 billion, while capital spending and shareholder returns stayed manageable relative to the group’s cash generation. The dividend increase to $1.30 per quarter for 2026 extends a long record of annual payout growth and adds another visible metric for income-focused holders.

Margins still carry the story

Johnson & Johnson’s 2025 numbers show a business that is still built on breadth rather than one product cycle. Revenue, margin, and per-share earnings all moved in the same direction in 2025, which is the combination the market usually rewards for a large health care company.

The comparison with 2024 is straightforward: sales rose 5.2%, adjusted EPS rose 6.0%, and operating margin stayed above 16%. That mix is more informative than any short-term price headline because it shows the earnings engine was still working at year-end 2025.

Pharmaceutical scale drives cash

The pharmaceutical segment remains the largest product engine inside Johnson & Johnson, supported by therapies such as Darzalex, Stelara, and Tremfya. The company’s 2025 annual report showed that Innovative Medicine contributed the bulk of sales, while MedTech added another important layer of diversification.

That mix matters because it spreads demand across chronic care, oncology, immunology, and devices instead of relying on a single franchise. For a company of this size, segment balance is part of the valuation story as much as headline growth.

Market value and trading context

Johnson & Johnson stock is listed on the New York Stock Exchange under NYSE: JNJ and belongs to the S&P 500 health care group. In the absence of a fresh dated quote in this research pass, the most durable market reference is the company’s large-cap income profile and the 2025 earnings base of $10.57 per share.

For investors reading the stock through a quality lens, the key comparison is not a single session move but the company’s ability to turn $88.8 billion in 2025 sales into $10.57 in adjusted EPS and a 16.2% margin. That is the core support for Johnson & Johnson stock as the 2026 guidance year begins.

Darzalex stays central

Among Johnson & Johnson products, Darzalex remains one of the most important commercial names in oncology, and it is a major reason the company can still post multi-billion-dollar quarterly revenue from its Innovative Medicine unit. In 2025, management continued to highlight portfolio depth rather than dependence on a single product.

That product spread gives the company more ways to protect the earnings base if one line softens. It also helps explain why the business can keep funding dividends, development, and litigation management at the same time.

NYSE scale remains the reference

Johnson & Johnson stock is a large, global health care equity with a wide shareholder base and a long dividend record. The company’s 2025 results and 2026 guidance provide the most useful current lens for the shares, even without a fresh market quote in this search pass.

As of 19 July 2026, the most important figures remain the 2025 sales level of $88.8 billion, adjusted EPS of $10.57, and 2026 sales guidance centered near $91.0 billion at the midpoint.